Innovative pricing solutions
We focus on innovative medicines and diagnostics that bring significant benefits to patients, their caregivers, physicians and other healthcare providers, payers and society on the whole.
Scientific advancements and technological capabilities are enabling more meaningful treatment options, but healthcare systems are facing budgetary constraints that could restrict use of new therapies. In order to be able to deliver benefits to patients, our products must be within reach of those who need them. At Roche we are putting into practice personalised reimbursement models (PRM) and international differential pricing (IDP), two innovative pricing solutions, to broaden access to our medicines. We are committed to working with our stakeholders so that payers and healthcare authorities have more flexibility when it comes to reimbursement decisions. We believe this approach will help to ensure continued access to innovative medicines for patients.
We are committed to work with all partners in the healthcare sector to find solutions that will be sustainable for all.
About Personalised Reimbursement Models
PRM allows medicines to be priced in line with the benefit they deliver to patients in different indications and combinations. PRM uses drug utilisation data to track the use of the medication and gain important insights into how a medicine is being used. We believe PRM will accelerate patient access to innovation and reduce financial pressure on prescribing by enabling the benefit of a medicine to be better reflected in its price.
This approach builds on the experience of the Italian Medicines Agency (AIFA) registries that have been running since 2006. Pilot projects are currently ongoing across Europe. Read more on PRM here.
International Differential Pricing
IDP guidelines align the prices public healthcare systems pay for our new medicines with the relative incomes of emerging markets and developing countries.
IDP applies to all innovative products and will permit greater price flexibility for the public market at the time of, or shortly after, launch. The model is based on Gross Domestic Product per capita, which is adjusted for Purchasing Power Parity (GDP-PPP per capita).
Price differentiation between countries with different economic strength has been shown to greatly improve patient access to innovative medicines in developing countries when price is a primary barrier. We expect IDP will facilitate broader and faster access to our medicines in emerging markets.